Shingles are the reactivation of a viral infection in the nerves to the skin that causes pain, burning, or a tingling sensation, along with an itch and blisters in the skin supplied by the affected nerve. It is caused by the varicella-zoster virus, or VZV—the same virus that causes chickenpox. When the itchy red spots of childhood chickenpox disappear, the virus remains in a dormant state in our nerve cells, ready to strike again in later life. This second eruption of the chickenpox virus is called shingles or herpes zoster.
You cannot develop shingles unless you have had earlier exposure to chickenpox. Shingles occur when an unknown trigger causes the virus to become activated. Most adults who have the dormant virus in their bodies never get shingles.
What are the symptoms and signs of shingles?
The first symptom of shingles is often burning or tingling pain, or itch, generally in a band-like distribution on one side of the body, i.e., around the waist, chest, stomach, or back. Shingles’ pain can be mild or intense. Some people have mostly itching; some feel severe pain from the gentlest touch, such as the weight of bed linens or clothing. A few people may have general symptoms of a viral infection, like fatigue, fever, and headache.
After several days or up to two weeks after the first symptoms are felt, a rash of fluid-filled blisters (vesicles) appears. These are similar to chickenpox but occur in a cluster rather than scattered over the body. The number of vesicles is variable. Some rashes merge and produce an area that looks like a burn. Other people may have just a few small scattered lesions. The clusters most often appear in a band called a dermatome, which contains nerves that branch out from the virus-affected nerve root exiting the spine. The second most common location is on one side of the face around the eye and on the forehead. However, shingles can involve any part of the body, including internal organs.
Recent studies have shown that subtle cases of shingles with only a few blisters, or none, are more common than previously thought. These cases may remain unrecognized.
Before the rash breaks out you usually feel tired and run-down. You may also have a slight fever and tingling sensations under your skin. The typical symptoms of shingles start 2 or 3 days later:
-
moderate to severe stinging or burning pain in the affected area,
-
followed by slightly reddish patches of skin with small bumps,
-
which then turn into small blisters that may be itchy in just a few hours.
This stage can last up to five days. After that, the blisters dry up in 2 to 10 days, leaving behind yellowish scabs.
The shingle rash generally affects only one side of the body and typically forms a band across the skin.
What is the varicella-zoster virus and how does it cause shingles?
The word “varicella” is derived from “variola,” the Latin word for smallpox. “Zoster” is the Greek word for girdle; shingles often produce a girdle or belt of blisters or lesions around one side of the waist. This striking pattern also underlies the condition’s common name: shingles come from “cingulum,” the Latin word for belt or girdle.
VZV belongs to a group of viruses called herpes viruses. This group includes the herpes simplex virus (HSV) that causes cold sores, fever blisters, and genital herpes. Like VZV, HSV can hide in the nervous system after initial infection and then travel down nerve cell fibers to cause a renewed infection. Repeated episodes of cold sores on the lips are the most common example.
Most adults in the United States have had chickenpox, even if it was so mild as to pass unnoticed, and they are at risk for developing shingles later in life. In the original exposure to VZV (chickenpox), some of the virus particles settle into nerve cells (neurons) of sensory ganglia (a group of nerve cells that connect the sensory periphery and central nervous system), where they remain for many years in an inactive, hidden (latent) form. The neurons in the sensory ganglia have nerve fibers that supply the skin and relay information to the brain about what the body is sensing—heat, cold, touch, pain.
When the VZV reactivates, it spreads down the long nerve fibers (axons) that extend from the sensory cell bodies to the skin. As the virus multiplies, the telltale rash erupts. With shingles, the nervous system is more deeply involved than it was during the bout with chickenpox, and the symptoms are often more complex and severe.
How are chickenpox and shingles different?
When a person, usually a child, who has not received the chickenpox vaccine is exposed to VZV, he or she usually develops chickenpox, a highly contagious disease that can be spread by breathing as well as by contact with the rash. The infection begins in the upper respiratory tract where the virus incubates for 15 days or more. VZV then spreads to the bloodstream and migrates to the skin, giving rise to the familiar chickenpox rash.
In contrast, you can’t catch shingles from someone else. You must already have been exposed to chickenpox and harbor the virus in your nervous system to develop shingles. When reactivated, the virus travels down nerves to the skin, causing the painful shingles rash. In shingles, the virus does not normally spread to the bloodstream or lungs, so the virus is not shed in air.
But a person with a shingles rash—which contains active virus particles—can pass the virus to someone who has never had chickenpox or who has not been vaccinated. In this case, the person will develop chickenpox, not shingles. A person must come into direct contact with the open sores of the shingles rash. Merely being in the same room with someone who has shingles will not cause chickenpox. Children who develop chickenpox generally fully recover; however, adults who develop chickenpox can become seriously ill.
Likewise, a person with chickenpox cannot give shingles to someone else—but they can pass the virus to someone who has never had chickenpox.
Who is at risk for shingles?
Anyone who had previously had chickenpox is at risk for shingles. About 25 percent of all adults, mostly otherwise healthy, will get shingles during their lifetime, usually after age 50. The incidence increases with age so that shingles is 10 times more likely to occur in adults over 60 than in children under 10. People with compromised immune systems, a natural consequence of aging or from the use of immunosuppressive medications such as prednisone, are at increased risk of developing shingles. Immune-suppressive drugs are used to treat serious illnesses such as cancer or from chemotherapy or radiation treatment, or from infection with HIV. Some individuals can also have re-eruptions and some, particularly those with significantly impaired immunity from drugs and diseases, may have shingles that spread over the body.
Youngsters whose mothers had chickenpox late in pregnancy—5 to 21 days before giving birth—or who had chickenpox in infancy have an increased risk of pediatric shingles. Sometimes these children are born with chickenpox or develop a typical case within a few days
How are shingles treated?
Currently, there is no cure for shingles, but attacks can be made less severe and shorter by using prescription antiviral drugs such as acyclovir, valacyclovir, or famciclovir as soon as possible after symptoms begin. Early treatment can reduce or prevent severe pain and help blisters dry faster. Antiviral drugs can reduce by about half the risk of being left with postherpetic neuralgia, which is chronic pain that can last for months or years after the shingles rash clears. Doctors recommend starting antiviral drugs at the first sign of the shingles rash, or if the telltale symptoms indicate that a rash is about to erupt. Other treatments to consider are anti-inflammatory corticosteroids such as prednisone. These are routinely used when the eye or other facial nerves are affected.
Most people with shingles can be treated at home.
People with shingles should also try to relax and reduce stress (stress can make pain worse and lead to depression); eat regular, well-balanced meals; and perform gentle exercises, such as walking or stretching to keep active and stop thinking about the pain (but check first with your physician). Placing a cool, damp washcloth on the blisters—but not when wearing a topical cream or patch—can help blisters dry faster and relieve pain. Keeping the area clean can help avoid a secondary bacterial infection.
Can shingles be prevented?
Shingles vaccine
In May 2006, the Food and Drug Administration (FDA) approved a VZV vaccine (Zostavax) for use in people 60 and older who have had chickenpox. In March 2011, the FDA extended the approval to include adults ages 50-59. A new shingles vaccine called Shingrix was licensed by the FDA in 2017 for adults age 50 and older. Talk with your healthcare professional if you have questions about shingles vaccination.
The Shingles Prevention Study—a collaboration between the Department of Veterans Affairs, the National Institute of Allergy and Infectious Diseases, and Merck & Co., Inc.—involved more than 38,000 veterans aged 60 and older. The purpose was to find out how safe the vaccine is, and if it can prevent shingles. Half the study participants received the shingles vaccine, and half received a similar-looking, inactive vaccine (placebo vaccine). Neither volunteers nor researchers knew if a particular subject had gotten an active or placebo vaccine until after the end of the study (called a double-blind study). During more than 3 years of follow-up, the vaccine reduced shingles cases by 51 percent; 642 cases of shingles developed in the placebo group compared with only 315 in the vaccinated group. And in people who received the active vaccine and still got shingles, the severity and discomfort were reduced by 61 percent. The vaccine also reduced the number of cases of long-lasting nerve pain (postherpetic neuralgia) by two-thirds compared with the placebo.
The shingles vaccine is a preventive therapy and not a treatment for those who already have shingles or postherpetic neuralgia.
Chickenpox vaccine
The chickenpox vaccine became available in the United States in 1995. Immunization with the varicella vaccine (or chickenpox vaccine)—now recommended in the United States for all children between 18 months and adolescence—can protect people from getting chickenpox. People who have been vaccinated against chickenpox are probably less likely to get shingles because the weak, “attenuated” strain of virus used in the chickenpox vaccine is less likely to survive in the body over decades.
What is postherpetic neuralgia?
Sometimes, particularly in older people, shingles pain persists long after the rash has healed. This is postherpetic neuralgia, defined as pain lasting three months after onset of the rash. Pain can be mild or severe—the most severe cases can lead to insomnia, weight loss, depression, and disability. There may be other sensations, such as tingling, coldness, or loss of feeling. About 20 percent of people age 70 or greater who develop shingles may have long-lasting pain. Postherpetic neuralgia is not directly life-threatening and may get better over time.
About a dozen medications in four categories have been shown in clinical trials to provide some pain relief for postherpetic neuralgia. These include:
Tricyclic antidepressants (TCAs): TCAs are often the first type of drug given to people suffering from postherpetic neuralgia. The TCA amitryptiline was commonly prescribed in the past, but although effective, it has a high rate of side effects. Desipramine and nortriptyline have fewer side effects and are therefore better choices for older adults, the most likely group to have postherpetic neuralgia.
Common side effects of TCAs include dry eyes and mouth, constipation, and impaired memory. People with heart arrhythmias (irregular heartbeats), previous heart attacks, or narrow angle glaucoma should usually use a different class of drugs.
Anticonvulsants: Some drugs developed to reduce seizures can also treat postherpetic neuralgia because seizures and pain both involve abnormally increased firing of nerve cells. The antiseizure medication gabapentin is most often prescribed. Carbamazepine is effective for postherpetic neuralgia but has somewhat common side effects including drowsiness or confusion, dizziness, and sometimes ankle swelling. Some small studies have shown positive effects using divalproex sodium to treat postherpetic neuralgia.
Opioids: Opioids are strong pain medications used for all types of pain. They include oxycodone, morphine, tramadol, and methadone. Opioids can have side effects—including drowsiness, mental dulling, and constipation—and can be addictive, so their use must be monitored carefully in those with a history of addiction.
Topical local anesthetics: Local anesthetics are effective when applied directly to the skin of the painful area affected by postherpetic neuralgia. Lidocaine, the most commonly prescribed, is available in cream, gel, or spray form. It is also available in a patch that has been approved by the FDA for use specifically in postherpetic neuralgia. With topical local anesthetics, the drug stays in the skin and therefore does not cause problems such as drowsiness or constipation. Capsaicin cream may be somewhat effective and is available over the counter, but most people find that it causes severe burning pain during application. An alternative approach using a high concentration capsaicin patch has been reported to be effective.
Postherpetic itch
The itch that sometimes occurs during or after shingles can be quite severe and painful. Clinical experience suggests that postherpetic itch is harder to treat than postherpetic neuralgia. Topical local anesthetics (which numb the skin) provide substantial relief to some individuals. Since postherpetic itch typically develops in the skin that has a severe sensory loss, it is particularly important to avoid scratching. Scratching numb skin too long or too hard can cause injury.
What are other complications of shingles?
Complications of zoster are more frequent in people with lesions in or around the eyes, forehead, and nose (ophthalmic shingles), or around the ear and on the face (herpes zoster oticus or Ramsay-Hunt syndrome). People with shingles in or near the eye should see an ophthalmologist immediately, as they can suffer painful eye infections and, in some cases, temporary or permanent vision loss. Symptoms can include redness and swelling involving just the white of the eye (sclera), the clear front of the eye (cornea), or internal parts of the eye. If the cornea is involved, treatment to avert permanent scarring is important to preventing lasting vision loss. The disease can cause damage to or death of the nerve cells that react to light (called acute retinal necrosis).
Shingle infections within or near the ear can cause hearing or balance problems as well as weakness of the muscles on the affected side of the face. These problems can be long-lasting or permanent.
In rare cases, shingles can spread into the brain or spinal cord and cause serious complications such as stroke or meningitis (an infection of the membranes outside the brain and spinal cord).
The varicella-zoster virus also may involve blood vessels or provoke an immune reaction irritating the surface of blood vessels (vasculopathy). People with shingles have a slightly increased risk of stroke, greatest in the first few weeks after vesicle eruption, but lasting for several months. The risk of stroke is highest in people with eye zoster, perhaps as much as five percent.
People with shingles need to seek immediate medical evaluation if they notice neurological symptoms outside the region of the primary shingles attack. People who are immunosuppressed, whether from diseases such as HIV or medications, have an increased risk of serious complications from shingles. They may develop shingles that spread to involve more parts of the body, or shingles rashes that persist for long periods or return frequently. Many such individuals are helped by taking antiviral medications on a continuous basis. People taking immunosuppressive drugs, or with diseases such as HIV or leukemia, should see a doctor immediately for treatment to avoid possible serious complications.
Can infection with VZV during pregnancy harm the baby?
Some infections can be transmitted across the mother’s bloodstream to the fetus or can be acquired by the baby during the birth process. Chickenpox during pregnancy poses some risk to the unborn child, depending upon the stage of pregnancy. During the first 30 weeks, maternal chickenpox may, in some cases, lead to congenital malformations (although such cases are rare). Most experts agree that shingles in a pregnant woman are even less likely to cause harm to the unborn child.
If a pregnant woman gets chickenpox between 21 to 5 days before giving birth, her newborn can have chickenpox at birth or develop it within a few days. But the time-lapse between the start of the mother’s illness and the birth of the baby generally allows the mother’s immune system to react and produce antibodies to fight the virus. These antibodies can be transmitted to the unborn child and thus help fight the infection. Still, a small percent of the babies exposed to chickenpox in the 21 to 5 days before birth develop shingles in the first 5 years of life because the newborn’s immune system is not yet fully functional and capable of keeping the virus latent.
If a mother contracts chickenpox at the time of birth, the newborn will have little ability to fight off the attack because its immune system is immature. If these babies develop chickenpox as a result, it can be fatal. They are given zoster immune globulin, a preparation made from the antibody-rich blood of adults who have recently recovered from chickenpox or shingles, to lessen the severity of their chickenpox.
What research is being done?
The mission of the National Institute of Neurological Disorders and Stroke (NINDS) is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. The NINDS is a component of the National Institutes of Health, the leading supporter of biomedical research in the world.
The NINDS funds and conducts research on a wide range of neurological disorders, such as shingles, to understand their causes and to develop and improve ways to diagnose, treat, and prevent them.
Medical research on shingles has two main goals. The first is to develop drugs to fight the disease and to prevent or treat its complications. The second is to understand the disease well enough to prevent it, especially in people at high risk. To achieve these goals, scientists need to learn much more about VZV and its effects, including how it becomes latent in nerve cells (neurons), what induces it to become active again, and how such reactivation can lead to postherpetic neuralgia and other complications..
For example, the NINDS supports research on the interplay between the viral proteins and virus defense mechanisms in neurons to understand why the varicella-zoster virus establishes latency uniquely in neurons and not in other cell types. Other studies focus on how VZV travels along sensory nerve fibers, or axons, and its role in latency and viral reactivation. Scientists also hope to identify molecular mechanisms that regulate the expression of latent viral genes, which may lead to targeted therapy to prevent reactivation.
Research on postherpetic neuralgia includes studies in animal models of the condition, to better understand cellular changes that lead to persistent pain. These changes may represent future targets in the form of improved vaccines, new medicines, or even gene therapy.
Antiviral Therapy
The oral antiviral agents’ acyclovir (Zovirax), valacyclovir (Valtrex), and famciclovir (Famvir, Novartis) have been shown to reduce the severity and duration of VZV infection,[rx] and these drugs are considered the mainstays of herpes zoster therapy.[rx,rx,rx] Topical antiviral agents are ineffective for the treatment of herpes zoster and are not recommended.[rx]
Antiviral Agents Used in the Treatment of Herpes Zoster in Immunocompetent Adults
| Drug | Dosage | FDA Approval? | Generic Version Available? | Average Wholesale Price (Generic) for 7 Days of Therapy |
|---|---|---|---|---|
| Acyclovir (Zovirax, Valeant) | 800 mg every 4 hours (five times daily) for 7 to 10 days | Yes | Yes | $128.33 |
| Famciclovir (Famvir, Novartis) | 500 mg every 8 hours (three times daily) for 7 days | Yes | Yes | $266.06 |
| Valacyclovir (Valtrex, GlaxoSmithKline) | 1,000 mg every 8 hours (three times daily) for 7 days | Yes | Yes | $265.63 |
The earlier that antiviral therapy is initiated after the presentation of herpes zoster symptoms, the greater the likelihood of clinical response.[rx] Most trials of zoster treatments enroll patients within 72 hours after the onset of a rash; acyclovir was reported to be most effective when administered within 48 hours after rash onset.[rx] However, limiting the use of antiviral drugs to the treatment of early symptoms may deny the potential benefits of these agents to zoster patients who still require treatment after the customary 72-hour therapeutic window.[rx,rx] In an observational study of valacyclovir, DeCriox et al. observed no difference in the duration of zoster-associate d pain and paresthesia in patients treated within 72 hours after the onset of rash and in patients treated after that period.]rx]
Acyclovir. Acyclovir is considered the “gold standard” of treatment.[rx] However, the drug’s clinical use is limited by its multiple-dosing schedule[tx] and less favorable pharmacokinetic profile compared with that of the second-generation antivirals valacyclovir and famciclovir.67 So far, VZV resistance to acyclovir has not been a major concern. Resistance in immunocompromised patients might be expected to increase, however.[rx]
Valacyclovir. As the oral prodrug of acyclovir, valacyclovir is a safe and effective alternative to its parent compound.74 A valacyclovir dose (1,000 mg three times daily for 7 or 14 days) was compared with acyclovir (800 mg five times daily for 7 days) in a randomized, double-blind study involving immunocompetent adults.[rx] Valacyclovir significantly accelerated the resolution of herpes zoster–associated pain at both 7 days compared with acyclovir. However, cutaneous manifestations resolved at similar rates with both drugs.
Famciclovir. Famciclovir, the prodrug of penciclovir, has more extensive bioavailability compared with acyclovir, and its active metabolite has a longer half-life, allowing a simpler dosing regimen (500 mg every 8 hours for 7 days vs. 800 mg five times daily for 7 to 10 days, respectively).[rx]
Shafran et al. compared famciclovir and acyclovir in immunocompetent adults in a randomized, double-blind trial.[rx] The primary efficacy endpoint was the time to full crusting of zoster lesions (i.e., lesion duration). The median times to crusting did not differ significantly between the two drugs.
In another study, famciclovir and acyclovir were clinically and statistically equivalent in terms of preventing the formation of new zoster lesions.[rx]
Foscarnet. Foscarnet (Foscavir) an organic analog of inorganic pyrophosphate, is approved only for the treatment of acyclovir-resistant herpes simplex virus.[rx] However, several case reports and small studies have described the successful treatment of VZV infection with this drug, particularly in AIDS patients.[rx] The clinical use of foscavir may be limited by its toxic effects, which include acute renal failure, gastrointestinal symptoms, genital ulcers, and seizures.[rx]
Britain. A nucleoside analog, brivudin (CAS 69304-47-8, Santa Cruz Biotechnology) is highly selective for VZV. The drug is not currently available in the U.S., but it was shown to be equivalent to famciclovir in a randomized, double-blind, multinational study.[rx] The drug’s once-daily dosing may make it the optimal choice for the treatment of herpes zoster in elderly patients.
Immunocompromised Patients. Individuals with compromised immunity are at increased risk for the development of herpes zoster. Those at greatest risk include patients with lymphoproliferative malignancies, organ transplant recipients, patients receiving systemic corticosteroids, and patients with AIDS.[rx’ Intravenous (IV) acyclovir (10 mg/kg every 8 hours) remains the treatment of choice for herpes zoster in severely immunocompromised patients. IV antiviral treatment can be replaced by oral therapy after the infection is under control.rx’]
Ocular Involvement. If untreated, herpes zoster ophthalmicus can lead to chronic ocular inflammation, debilitating pain, and blindness.[rx] The most effective drugs for treating this disorder appear to be acyclovir, valacyclovir, and famciclovir. Additional management of associated symptoms, such as dry eye and glaucoma, may be warranted.]rx]
Therapy for Acute Pain
The acute pain of herpes zoster has a profound effect on health-related QOL.[rx] When clinicians consider the treatment of zoster-associated pain, however, they often focus on the chronic pain of PHN. The literature regarding the treatment of acute zoster pain is limited. Typically, narcotic analgesics, tricyclic antidepressants, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen are added to antiviral therapy, with varying degrees of efficacy.[rx,rx] The treatment of choice depends on the severity of the pain. More studies are needed to determine the most appropriate therapies for acute zoster pain.
Antiviral Therapy. Acute pain may be reduced if appropriate antiviral therapy is started within 72 hours after zoster symptoms appear,[rx] although patients will still be at risk for the development of PHN.
Analgesic Drugs. A randomized, placebo-controlled study compared controlled-release oxycodone (OxyContin, Purdue Pharma) with gabapentin (Neurontin, Pfizer) in patients with the acute pain of herpes zoster.[rx] Patients treated with oxycodone experienced significant pain relief compared with that given placebo during the first 14 days of treatment, whereas gabapentin-treated patients did not show any difference compared with the placebo group. Oral analgesics may be used to treat acute pain in zoster patients with ocular involvement. Clinicians should never instill topical anesthetics directly onto the cornea in these patients.[rx]
Opioids. Elderly patients might not be able to tolerate high doses of opioids and therefore might not achieve maximum pain control with these drugs. Kanodia et al. compared the efficacy of gabapentin and placebo in geriatric patients with acute herpetic neuralgia.[rx] Patients received 300, 600, or 900 mg of gabapentin daily. By the fourth week, pain-scale scores were significantly improved (P < 0.001) in all three treatment groups compared with the placebo group.
Corticosteroids. The use of systemic corticosteroids to treat the acute pain of herpes zoster is controversial. Articles about corticosteroid therapy in zoster patients often include recommendations based on judgment and experience rather than on clinical evidence.[rx]According to one report, corticosteroids were found to offer a slight benefit in preventing acute zoster-associated pain.[rx] However, the risks of using corticosteroids to treat herpes zoster may outweigh any potential benefits in patients with concomitant conditions that can be exacerbated by these drugs.[rx] If it is decided to begin the treatment of zoster pain with corticosteroids, they should be administered only in combination with antiviral agents.[tx,rx] The treatment of herpes zoster with topical corticosteroids is not recommended.
Aspirin. Topical aspirin has been studied in a number of different vehicles for the treatment of acute herpetic neuralgia. Balakrishnan et al., for example, studied the effects of a compounded topical aspirin/moisturizer combination versus oral aspirin.[rx] The authors concluded that the local analgesic effect of topical aspirin in a moisturizer was superior to the analgesia achieved with oral aspirin in relieving the acute pain of herpes zoster.
Therapy for Chronic Pain
The goal of any treatment approach to herpes zoster is to prevent complications and long-term sequelae. In this regard, the early use of antiviral drugs may help to reduce the development of PHN.[rx] A literature review found little support for the use of corticosteroids for preventing PHN.[rx]
Managing the chronic pain of PHN is a complicated process, and current treatment modalities are often unsatisfactory.[5x] Studies have shown that some drugs, including analgesics, anesthetics, narcotics, tricyclic antidepressants, and anti-epileptic agents, may provide at least partial pain relief.[rx,rx] For the effective treatmerx]nt of PHN, it may be necessary to administer drug combinations for extended periods in order to achieve sufficient relief. Further research is needed to identify effective targeted therapies.
Analgesic Drugs. Patients with mild-to-moderate PHN may benefit from acetaminophen, aspirin, or NSAIDs such as ibuprofen. These drugs rarely provide complete pain relief, however, and combination therapy with stronger analgesics may be necessary. For optimal pain control, it is important that clinicians prescribe these medications around the clock rather than as needed.[rx] Neuropathic pain, such as PHN, is generally less responsive to analgesic drugs than non-neuropathic pain.[rx]
Opioids. Experts have long debated the use of opioids in the management of chronic neuropathic pain.[rx,rx] Data from randomized controlled trials suggest that these drugs may be useful in relieving PHN,[rx–rx] but more studies are needed to determine their long-term benefits. Opioids may be considered for patients with moderate-to-severe PHN or with PHN-related sleep disturbances as part of a comprehensive treatment plan.]rx]
The general principles of pain control with opioids for PHN include titrating the dose to achieve optimal efficacy while reducing side effects, documenting the treatment plan and outcomes, monitoring side effects, and adding a prophylactic laxative to prevent constipation.[rx] Clinicians should use a controlled-release opioid regimen and should be prepared to provide immediate breakthrough analgesia.
The adverse effects associated with opioids, including constipation, nausea, confusion, and sedation, are of particular concern in elderly patients, and opioids should be used with caution in these individuals.
Tramadol (Ultram, Janssen), a centrally-acting opioid, has been effective in treating the pain associated with polyneuropathy.[rx–rx] In a randomized, double-blind, placebo-controlled study, extended-release tramadol achieved a significant (P = 0.031) reduction in pain intensity compared with placebo over a 6-week period in patients with PHN.[rx] Clinicians should closely monitor the adverse effects of tramadol, which include nausea, dizziness, and constipation.
Tricyclic Antidepressants. Tricyclic antidepressants (TCAs) are widely used for the management of neuropathic pain.[rx] Early treatment with low-dose amitriptyline has been shown to reduce the pain of PHN by more than 50% compared with placebo (P < 0.05).96 Amitriptyline or its metabolite, nortriptyline (Pamelor, Mallinckrodt), appears to be the standard of care for the management of most forms of neuropathic pain.[rx] However, nortriptyline and desipramine (Norpramin, Sanofi) may be preferred over amitriptyline and imipramine (Tofranil, Mallinckrodt) because of their lower risk of adverse effects.[rx,rx]
The anticholinergic side effects of TCAs, such as dry mouth, drowsiness, and constipation, must be closely monitored when these drugs are administered to elderly patients.
Anticonvulsant Drugs. Because of their ability to reduce neuronal derangement, anticonvulsant drugs may be used to treat PHN.[rx] Gabapentin is a well-established therapy for neuropathic pain and has demonstrated clinical benefit in patients with PHN.[rx,rx,rx,rx]
Pregabalin (Lyrica, Pfizer), a newer anticonvulsant drug, has been found to be effective in treating PHN in several randomized controlled trials.[rx] Freynhagen et al. reported that both fixed-dose and flexible-dose pregabalin were significantly more effective than placebo (P = 0.002) in reducing pain scores in patients with neuropathic pain.[rx]
Dose adjustments are required for both gabapentin and pregabalin in patients at risk of renal impairment. Patients treated with either drug must be monitored for adverse effects, including dizziness, somnolence, and peripheral edema.
Topical Therapy. Elderly patients may be intolerant of oral medications that are used to manage PHN. Investigators have therefore given increased attention to topical therapies that may help to relieve the pain associated with herpes zoster.
Lidocaine. Lidocaine 5% (Lidoderm, Endo) has been administered successfully as a topical patch for the treatment of PHN[rx,rx] and may be considered a first-line treatment in this setting.[rx]
Piroxicam. A study conducted in Korea compared a topical piroxicam patch (Feldene, Pfizer; not approved in the U.S.) with the lidocaine patch in patients with PHN.[rx] The lidocaine patch was more effective in treating allodynia, whereas the piroxicam patch was more effective in treating dull pain. Although the results of this study did not demonstrate the clear superiority of one patch over another, more trials of this kind are needed to identify effective therapies for PHN.
Capsaicin. Capsaicin (the main capsaicinoid in chili peppers) works by desensitizing sensory nerve fibers. Topical capsaicin has proved beneficial for the treatment of neuropathic pain in a few clinical trials, but the pain relief that the drug elicits may be delayed. Moreover, adverse effects, such as stinging and burning at the application site, may limit its use, particularly in the elderly.[rx] Topical capsaicin has been approved as a patch (Qutenza, NeurogesX) for the relief of neuropathic pain associated with PHN.[rx] Up to four patches may be applied to the skin for a total of 60 minutes every 3 months.
Alternative Therapies
In response to the dose-limiting adverse effects associated with current PHN therapies, investigators have studied the clinical efficacy of complementary and alternative medicine (CAM) in reducing the pain of PHN.[rx,rx] Alternative approaches include acupuncture, neural therapy, cupping and bleeding, meditation, and the ingestion of Chinese herbs. All of these strategies have shown some benefit in reducing pain symptoms when used in conjunction with conventional medical treatments. Although the suggested pain-relieving effects of alternative therapies have not been studied on a large scale, these approaches may offer a way to improve the quality of life of patients with PHN.
References
People Also Reading
